---
title: "Many listed companies have taken repurchase actions in the first month of the new year"
description: "Since 2026, the trend of share buybacks among listed companies has continued. In January, several A-share companies implemented buybacks, including BUCHANG PHARMA and Xingfa Chem. Huasheng Lithium Bat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274571997.md"
published_at: "2026-02-02T23:53:43.000Z"
---

# Many listed companies have taken repurchase actions in the first month of the new year

> Since 2026, the trend of share buybacks among listed companies has continued. In January, several A-share companies implemented buybacks, including BUCHANG PHARMA and Xingfa Chem. Huasheng Lithium Battery, RemeGen, and Yiyi Co., Ltd. adjusted their buyback prices due to stock prices exceeding the buyback limit. The main reason for the companies' buybacks is based on confidence in future development prospects, with repurchased shares often used for employee stock ownership plans or equity incentives

Since 2026, the trend of share buybacks by listed companies has continued. Since January, several A-share companies have implemented buybacks with "real money." Among them, BUCHANG PHARMA and Xingfa Chem quickly executed their buyback plans after disclosing them in January; Huasheng Lithium Battery, RemeGen, and Yiyi Co., Ltd. have significantly raised their buyback prices to ensure the smooth implementation of their buyback plans, as their stock prices have recently exceeded the upper limit of the buyback price. It can be seen that "confidence in the company's future development prospects and a fundamental judgment of the company's intrinsic value" have become important reasons for many companies to implement buybacks; the shares repurchased by the company are mostly planned for employee stock ownership plans or equity incentives. (Shanghai Securities Journal)

### Related Stocks

- [603858.CN - BUCHANG PHARMA](https://longbridge.com/en/quote/603858.CN.md)
- [688331.CN - RemeGen](https://longbridge.com/en/quote/688331.CN.md)
- [600141.CN - Xingfa Chem](https://longbridge.com/en/quote/600141.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ZAWYA-SNG: China’s Xingfa Group to evaluate phosphate and silica projects in Egypt’s Golden Triangle | Egypt’s Ministry of Petroleum and Mineral Resources has signed a memorandum of understanding with China’s Xingfa Group t | [Link](https://longbridge.com/en/news/273941457.md) |
| Buchang Pharma Gets Regulatory Approval for Drug Manufacturing License Changes | Buchang Pharma Gets Regulatory Approval for Drug Manufacturing License Changes | [Link](https://longbridge.com/en/news/267766651.md) |
| EKF Diagnostics Holdings Announces Share Buyback Programme For Up To 5 Million Shares | EKF Diagnostics Holdings PLC :EKF DIAGNOSTICS HOLDINGS PLC - ANNOUNCES SHARE BUYBACK PROGRAMME FOR UP TO 5 MILLION SHARE | [Link](https://longbridge.com/en/news/276310546.md) |
| Physitrack Intends To Implement Share Buyback Program | Physitrack PLC :BOARD APPROVES INTENTION TO IMPLEMENT SHARE BUYBACK PROGRAMTO REPURCHASE UP TO 10% OF ISSUED SHARE CAPIT | [Link](https://longbridge.com/en/news/276423338.md) |
| Buchang Pharma Signs Contract for Clinical Trial of Traditional Chinese Drug | Buchang Pharma Signs Contract for Clinical Trial of Traditional Chinese Drug | [Link](https://longbridge.com/en/news/267769427.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.